| Dr William Silverman, MD | |
|
1232 E Broadway Rd, Ste 120, Tempe, AZ 85282 | |
| (480) 784-1514 | |
| (480) 967-3528 |
| Full Name | Dr William Silverman |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 1232 E Broadway Rd, Tempe, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215993902 | NPI | - | NPPES |
| 14951 | Other | AZ | BOARD OF MEDICAL EXAMINER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 14951 (Arizona) | Primary |
| Entity Name | Empact- Suicide Prevention Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003982133 PECOS PAC ID: 2365416575 Enrollment ID: O20040824000311 |
News Archive
The first-ever randomized controlled trial on babies with CF has found that treatment with inhaled hypertonic saline can improve breathing and lung health.
Our brain recognizes objects within milliseconds, even if it only receives rudimentary visual information. Researchers believe that reliable and fast recognition works because the brain is constantly making predictions about objects in the field of view and is comparing these with incoming information.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."
In the mid-nineteenth century Charles Locock, physician to Queen Victoria, introduced bromide as the first effective treatment for epilepsy. The drug was little used in treating the disorder until 1868, however, when its efficacy against seizures was first demonstrated in a clinical trial. Bromide was the sole anticonvulsant available until 1912 and the introduction of phenobarbital.
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William Silverman, MD 1232 E Broadway Rd, Ste 120, Tempe, AZ 85282 Ph: (480) 784-1514 | Dr William Silverman, MD 1232 E Broadway Rd, Ste 120, Tempe, AZ 85282 Ph: (480) 784-1514 |
News Archive
The first-ever randomized controlled trial on babies with CF has found that treatment with inhaled hypertonic saline can improve breathing and lung health.
Our brain recognizes objects within milliseconds, even if it only receives rudimentary visual information. Researchers believe that reliable and fast recognition works because the brain is constantly making predictions about objects in the field of view and is comparing these with incoming information.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."
In the mid-nineteenth century Charles Locock, physician to Queen Victoria, introduced bromide as the first effective treatment for epilepsy. The drug was little used in treating the disorder until 1868, however, when its efficacy against seizures was first demonstrated in a clinical trial. Bromide was the sole anticonvulsant available until 1912 and the introduction of phenobarbital.
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout.
› Verified 5 days ago
Mrs. Luna Viva Ananda, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1642 S Priest Dr Ste 101, Tempe, AZ 85281 Phone: 480-929-5100 Fax: 480-731-1066 | |
Laurie Ramsbacher, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1501 W Fountainhead Pkwy, Suite 295, Tempe, AZ 85282 Phone: 866-495-6738 Fax: 800-398-6182 | |
Edward G Blankstein, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1050 E Southern C1, Tempe, AZ 85282 Phone: 480-966-1174 Fax: 480-858-0119 | |
Ms. Alverna Hess, MPAS, PA-C Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2034 E Southern Ave Ste D, Tempe, AZ 85282 Phone: 480-923-6200 Fax: 602-419-3101 | |
Dr. Mark Leslie Rubin, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2020 S. Mcclintock Dr.#105, Tempe, AZ 85282 Phone: 480-284-7304 Fax: 480-284-7616 | |
Sarita Vijay, NP Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1500 N Priest Dr Ste 109, Tempe, AZ 85288 Phone: 833-719-0886 |